– New brand reflects the company’s evolution to support market dynamics
– Company provides more than traditional consulting services
– Solutions to Chemistry, Manufacturing, & Controls challenges remains paramount
Southborough, MA, October 6, 2021 – Prabu Nambiar, Ph.D., Founder and Chief Executive Officer, announced today that Syner-G Pharma Consulting, LLC has finalized a refreshed brand identity and will now be known as Syner-G BioPharma Group.
According to Dr. Nambiar, “Since its founding, Syner-G has continually adjusted its offerings to reflect the dynamics of the market. We’ve been fortunate in that we provide a business model that complements the state of the industry, where virtual and outsourced development and CMC play a critical role in the launch of new drugs intended for unmet medical needs. Today, Syner-G offers a skill set that transcends traditional consulting services and is in high demand. We felt it was important to refresh our brand to reflect how we have evolved to date, as well as where we are heading in the future.”
The new brand reflects the core of Syner-G’s offering: a deep, diverse commitment to supporting companies across biopharma, including small molecules, biologics, cell and gene therapies, and medical devices. The company’s focus will continue to be on delivering solutions to a wide range of challenges faced by innovative life science companies in the area of Chemistry, Manufacturing, and Controls (CMC). Syner-G’s expertise is demonstrated in what the company calls CMC 360™: a fully integrated suite of CMC solutions encompassing pharmaceutical development, regulatory affairs and quality/cGxP compliance. When combined with a talented and dedicated team of full-time professionals who follow a science- and risk-based approach, the CMC 360 business model provides an efficient yet nimble resource for biopharma clients.
Dr. Nambiar added, “This is a really exciting time for Syner-G BioPharma Group. Our business is strong across all areas, we continue to expand our team, and we’ve recently received an investment from the private equity firm Riverside Partners to support Syner-G’s next stage of growth. A refreshed branding that’s in sync with our evolution is a natural step for a dynamic company such as ours.”
The look of the refreshed branding connotes the evolution of the company. The new Syner-G logo was designed in a modern style, while also connecting to the company’s history and legacy of success by maintaining the image of a tetrahedron with a more modern design. The tetrahedron image is integral to Syner-G’s CMC 360 core concept because it demonstrates how a number of elements come together synergistically to make the whole stronger and enduring.
For more information or to arrange a meeting with a Syner-G solution provider, email us at info@synergbiopharma.com or call 508.460.9700.
About Syner-G BioPharma Group
Syner-G BioPharma Group is the premier solution provider of Chemistry, Manufacturing, and Controls (CMC) services for the life sciences industry. The company’s approach is based on CMC 360™, a fully integrated suite of CMC solutions that encompasses pharmaceutical development, regulatory affairs, and quality/cGxP compliance. The entire Syner-G organization is built around the premise of guiding small molecule, biologics, cell and gene therapy, and medical device innovators through the CMC process. Since its founding in 2007, Syner-G has enabled clients in their quest to bring life-saving and life-enhancing products to patients. Today, the company has grown to more than 100 employees globally, been recognized as one of the “Top 10 Drug Development and Consulting Services Companies” by Pharma Tech Outlook, and served as an integral part of more than 500 various types of successful regulatory filings. For customers looking for offshore resources, Syner-G also offers CMC services based in India. Syner-G’s operations in India follow the same CMC 360™ model used in the U.S., further differentiating the company from typical CMC consultants. Learn more at www.synergbiopharma.com
Syner-G BioPharma Group Media Contact:
Maria Garvey
Delfino Marketing Communications, Inc.
914.747.1400
maria@delfino.com
About Riverside Partners
Founded in 1989, Riverside Partners is a middle market private equity firm with total capital commitments of $1.6 billion raised since inception. The firm focuses on growth-oriented companies in the healthcare and technology industries. Riverside Partners is particularly experienced at partnering with founders, owners and management teams and it brings substantial domain expertise and operating experience to its portfolio companies. For more information, visit www.riversidepartners.com.
Riverside Partners Media Contact:
Andy Merrill or Nick Rust
Prosek Partners
646.818.9252
amerrill@prosek.com / nrust@prosek.com